Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients
Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients
复制标题
DOI：
10.1111/j.1440-1746.2009.06037.x
复制
发表时间：
2010-02-01
影响因子：
4.1
通讯作者：
Onji, Morikazu
中科院分区：
文献类型：
--
作者：
Hiraoka, Atsushi;Michitaka, Kojiro;Onji, Morikazu
背景和目的：随着社会老龄化，日本老年肝细胞癌（HCC）患者的数量不断增加。日本政府将老年人定义为65岁以上，并将老年人分为两个阶段：第一老年阶段（< 75岁）和第二老年阶段（>= 75岁）。我们调查的有效性和安全性的射频消融治疗（RFA）的患者在第二个老年阶段与其他肝癌patients相比，retrospectively.Methods：206例肝癌患者，谁是米兰标准内，低级别的性能状态（0或1）和Child-Pugh分类的A或B。所有患者均于2000年1月至2008年12月接受射频消融治疗作为初始治疗，并分为老年肝癌组（e-HCC组; >= 75，n = 63）和非e-HCC组（< 75例，n = 143），比较其临床资料及生存率。年龄与维生素K缺乏或拮抗剂引起的蛋白质水平与非e-HCC组相比，e-HCC组的PIVKA-II水平较高（分别为78.3 +/- 3.2 vs 64.2 +/- 7.5岁，676.3 +/- 2643.7 vs 142.4 +/- 442.2 mAU/mL：P < 0.01）。两组之间的Child-Pugh分级、肿瘤淋巴结转移分期、日本综合分期评分以及3年和5年后的生存率无显著差异（e-HCC组：分别为82.5%和49.7%;非e-HCC组：分别为78.3%和57.5%）。有没有严重的并发症在e-HCC group.Conclusions：老年肝癌患者，谁有良好的性能状态，应在相同的方式和相同的策略，年轻的肝癌患者进行治疗。
Background and Aim: With the aging of society, the number of elderly patients with hepatocellular carcinoma (HCC) has been increasing in Japan. The Government of Japan defines elderly as being over 65 and has divided the elderly into two stages: the first elderly stage (< 75 years old) and the second elderly stage (>= 75). We investigated the efficacy and safety of radiofrequency ablation therapy (RFA) in patients in the second elderly stage in comparison with other HCC patients, retrospectively.Methods: Two hundred six patients with HCC, who were within the Milan criteria, with low-grade performance status (0 or 1) and a Child-Pugh classification of A or B were enrolled. All were treated with RFA from January 2000 to December 2008 as an initial therapy and were divided into elderly HCC group (e-HCC group; >= 75, n = 63) and non e-HCC group (< 75, n = 143), and their clinical data and survival rates were compared.Results: Age and the level of protein induced by vitamin K absence or antagonist (PIVKA-II) were higher in the e-HCC group as compared with the non e-HCC group (78.3 +/- 3.2 vs 64.2 +/- 7.5 years, 676.3 +/- 2643.7 vs 142.4 +/- 442.2 mAU/mL: P < 0.01, respectively). There were no significant differences for Child-Pugh class, tumor node metastasis stage, and Japan Integrated Stage score and in survival rates after 3, and 5 years between the groups (e-HCC group: 82.5% and 49.7%, respectively; non e-HCC group: 78.3% and 57.5%, respectively). There were no severe complications in the e-HCC group.Conclusions: Elderly HCC patients, who have good performance status, should be treated in the same manner and with the same strategy as young HCC patients.